Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Riboprine is a synthetic nucleoside analogue, specifically an isopentenyl derivative of adenosine. It belongs to the cytokinin family of plant growth regulators and occurs naturally in certain transfer RNAs. In biological systems, it has demonstrated antitumor (antineoplastic), antiviral, and plant growth regulatory activities. Mechanistically, riboprine acts as a nucleic acid synthesis inhibitor by interfering with RNA-dependent RNA polymerase (RdRp) and exoribonuclease (ExoN), key enzymes for viral replication—most notably showing potent inhibition against SARS-CoV‑2 in vitro. It can induce cell cycle arrest and apoptosis in mammalian cells[1][7][8]. Riboprine has been studied for potential use in cancer therapy as well as antiviral applications including COVID‑19.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on riboprine.